

RESEARCH

Open Access



Randomized comparison of effects of two different remifentanyl dose on surgical conditions during endoscopic sinus surgery

JinHyeok Jeong¹, ChanWoo Park², YoungJoon Yoon², DoJae Lee² and SangYun Cho^{2*}

Abstract

Background The combination of propofol and remifentanyl results in better surgical field conditions during endoscopic sinus surgery than inhalation anesthesia. This study compared surgical field conditions between two groups receiving low or high concentration of remifentanyl and hemodynamic variables using non-invasive cardiac monitoring.

Methods Fifty-four patients between ASA I or II, were randomly assigned to either the high-concentration remifentanyl group (HR), effect-site concentration of 8 ng/mL or the low-concentration remifentanyl group (LR), effect-site concentration of 4 ng/mL. Surgical condition was evaluated using the Boezaart Surgical Field Grading Scale presented by Boezaart. Cardiac output was measured using non-invasive cardiac monitoring (CSN-1901).

Results In terms of surgical conditions, the HR group showed significantly lower values than the LR group ($p=0.021$) at 90 min after the start of surgery. Heart rate was significantly lower in the HR group than the LR group at 30, 60, and 90 min after the start of surgery (30 min; $p=0.005$, 60 min; $p=0.002$, 90 min; $p=0.001$). There was a statistically significant decrease of cardiac output in the HR group compared to the LR group immediately after endotracheal intubation and at 30, 60, and 90 min after the start of surgery (Base; $P=0.222$, Intubation; $P=0.016$, 30 min; $p=0.014$, 60 min; $P=0.012$, 90 min; $P=0.008$). However, in the case of stroke volume, there was no significant difference between the two groups in all measurements.

Conclusion When comparing the HR group and the LR group, the surgical condition was improved at 90 min after the start of surgery. MAP was lower in the HR group and this was a result of reduction in cardiac output primarily attributed to the decrease in heart rate rather than a decrease in stroke volume.

Trial registration Clinical Trial Registry of the Republic of Korea (KCT0006453).

Keywords Endoscopic sinus surgery, Remifentanyl, Surgical field condition

Introduction

Endoscopic sinus surgery is a widely utilized treatment for sinusitis, often performed under general anesthesia [1]. However, a significant challenge in these procedures is the increased bleeding that occurs, leading to reduced visibility and difficulties in manipulating the endoscope [2]. This can hinder the surgeon's ability to effectively treat the underlying sinusitis.

*Correspondence:

SangYun Cho

chosy@hanyang.ac.kr

¹ Department of Otorhinolaryngology, Hanyang University Guri Hospital, Guri-Si, Gyeonggi-Do, Republic of Korea

² Department of Anesthesiology and Pain Medicine, Hanyang University Guri Hospital, 249-1, Gyomun-Dong, Guri-Si, Gyeonggi-Do 471-701, Republic of Korea



Reducing bleeding during endoscopic sinus surgery is of paramount importance as it directly impacts the surgical outcome and patient safety. Various approaches have been investigated to mitigate this issue, and one promising method involves the use of total intravenous anesthesia (TIVA) with a combination of the intravenous anesthetic, propofol and the opioid, remifentanyl [3]. Despite the potential benefits of TIVA, the optimal concentration of remifentanyl for achieving improved surgical conditions also remains unclear. Determining the most effective remifentanyl concentration is crucial for optimizing surgical outcomes and patient comfort. The specific concentration of remifentanyl that provides optimal surgical conditions while maintaining hemodynamic stability is an area that requires further investigation.

Therefore, the primary objective of this study is to compare the effects of high-concentration (effect site concentration of 8 ng/ml) remifentanyl and low-concentration (effect site concentration of 4 ng/ml) remifentanyl on surgical conditions during endoscopic sinus surgery. The dosage of remifentanyl was determined based on references from two papers, which have established a safe dosage for patients [4, 5]. While assessing the impact of remifentanyl concentration on bleeding control and surgical visualization, we also aim to explore hemodynamic variables such as cardiac output, stroke volume, heart rate, and mean arterial pressure to evaluate the stability and safety of each remifentanyl concentration using non-invasive cardiac monitoring.

Methods

Study subjects

The subjects were 54 patients between the ages of 18 and 65 years who were rated as American Society of Anesthesiology Classification I or II. Exclusion criteria were: 1) patients with allergies to eggs or soybean oil; 2) patients with a history of drug abuse; and 3) patients receiving other medical treatment, e.g., for hypertension, diabetes, or other conditions. After obtaining approval from the hospital's institutional review board (Hanyang University Guri Hospital Institutional Review Board, GURI 2021-03-041-006) and registering with the clinical research information service centre (KCT0006453, Date of registration: 17/08/2021, Principal Investigator: SY Cho), this study was performed in accordance with the relevant guidelines and regulations. This study was in accordance with the declaration of Helsinki. Written informed consent was obtained from the patients who voluntarily agreed to participate in the study.

Research methods

The study was based on a randomized trial and the subjects were randomly classified into computer-generated

numbers. Instructed nurses who did not know the study details randomly assigned the subjects by selecting high concentration and low concentration from a sealed envelope just before surgery. The allocation ratio was 1:1 for each group. After the patient arrived at the operating room, electrocardiogram, pulse oxygen saturation, non-invasive blood pressure, and end-tidal carbon dioxide pressure were measured. Depth of anesthesia was measured using a bispectral index (BIS) monitor (A-2000TM, version 3.3, Aspect Medical Systems Inc., Newton, MA, USA). After administering 100% oxygen for three min to the patient, 40 mg of 1% lidocaine was administered intravenously. Using a target concentration-controlled injector (Orchestra, Fresenius-Vial, Brezins, France), propofol was administered at an effect-site concentration of 6.0 µg/ml using a Schnider pharmacokinetic model. Remifentanyl was administered at an effect-site concentration of 2.0 - 4.0 ng/ml using the Minto pharmacokinetic model. During administration of propofol and remifentanyl, the patient received the instruction "open your eyes" every 10 s. If the patient could not open their eyes, the muscle relaxant rocuronium was injected at a dose of 0.6 mg/kg. When the BIS level dropped below 60 and the train of four (TOF) on the nerve stimulator reached zero, endotracheal intubation was performed.

Administration of remifentanyl during anesthesia maintenance was performed by a target-controlled infusion (TCI) device with an effective site concentration of 8 ng/ml in the high-concentration group and of 4 ng/ml in the low-concentration group. The TCI device was prepared in advance by an instructed nurse, and the fixed concentration of drug was sealed. The anesthesiologist who administered the anesthesia was, therefore, blinded to the concentration of remifentanyl used. The effect-site concentration of propofol was adjusted by 0.2 µg/ml from the initial concentration to maintain a BIS value of 40–60. Ephedrine was used 5–10 mg intravenously only when MAP falls below 60 mm Hg.

At the end of the operation, propofol and remifentanyl were discontinued; pyridostigmine 0.2 mg/kg and glycopyrrolate 0.008 mg/kg were injected intravenously to reverse the muscle relaxant effects; and extubation was performed under the influence of a nerve stimulator.

Baseline systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), heart rate (HR), BIS, stroke volume (SV), and cardiac output (CO) levels were measured immediately after arrival at the operating room. The variables also were measured immediately after endotracheal intubation and at 30, 60, and 90 min after the start of surgery, for observation and comparison. Stroke volume and cardiac output were measured using non-invasive cardiac monitoring, for which the CSN-1901 (Nihon Kohden,

Tokyo, Japan) was used. Evaluation of the surgical condition was conducted by a single operator using the Boezaart surgical field grading scale (Table 1) [6] and was recorded at 30, 60, and 90 min after the start of surgery. Although the type of surgery was the same, the pre-existing conditions of the patient varied slightly.

The total doses of propofol and remifentanyl administered during anesthesia were recorded.

After 30 min and within 24 h of recovery room arrival, the Visual Analog Scale (VAS) and Postoperative Nausea and Vomiting (PONV) score were measured. The PONV score was divided into 4 categories, 0 = none, 1 = nausea, 2 = retching, and 3 = vomiting. Ramosetron was given to the patients who experienced PONV.

Sample size calculation

We used the mean and standard deviation from pilot study (mean and standard deviation: 2.3 and 0.57). In a two-tailed analysis where $\alpha = 0.05$ and $\beta = 80\%$, 24.1 patients were required to obtain a 20% difference of the mean between the experimental and control groups. A total of 54 patients were required to maintain acceptable statistical power, assuming a 10% dropout rate. Sample Size Software, 3rd edition from Sample Size Tables for Clinical studies by David Machin, Michael Campbell, Say-Beng Tan et al. was used for calculation.

Statistics

The Statistical Package for Social Sciences 20.0 for Windows (SPSS Inc., IL, USA) was used as a statistical program. The Mann-Whitney rank sum test was performed to compare numerical data between the two groups, and the χ^2 test and Fisher's exact test were used for non-parametric data. Kruskal-Wallis one-way analysis of variance with a Dunn multiple comparison test was used to assess haemodynamic change. The statistical significance level was set at $p = 0.05$.

Results

All 54 patients who participated in the study met the inclusion criteria, and none refused to participate. These patients were randomly assigned to a high-concentration or low-concentration group, with 27 patients in each group (Fig. 1).

Subject data and clinical characteristics are presented in Table 2. There was no significant difference between the two groups in terms of mean age, gender, height, weight, body mass index, ASA score, and operation and anesthesia times.

Hemodynamic variables between the two groups were measured through non-invasive cardiac monitoring (Table 3). For cardiac output, there was a statistically significant decrease in the high concentration group compared to the lower concentration group immediately after endotracheal intubation and at 30, 60, and 90 min after the start of surgery (cardiac output, base; $p = 0.222$, intubation; $p = 0.016$, 30 min; $p = 0.014$, 60 min; $p = 0.012$, 90 min; $p = 0.008$). However, for stroke volume, there was no significant difference between the two groups in all measurements (stroke volume, base; $p = 0.482$, intubation; $p = 0.461$, 30 min; $p = 0.258$, 60 min; $p = 0.263$, 90 min; $p = 0.603$).

The changes in heart rate between the two groups (Fig. 2a) were significantly lower in the high-concentration group compared to the low-concentration group immediately after endotracheal intubation and at 30, 60, and 90 min after the start of surgery (heart rate changes, base; $P = 0.412$, intubation; $p = 0.033$, 30 min; $p = 0.005$, 60 min; $p = 0.002$, 90 min; $p = 0.001$). Mean arterial pressure (Fig. 2b) and systolic blood pressure (Fig. 2c) decreased in the high-concentration group compared to the low-concentration group immediately after endotracheal intubation and at 30 min after the start of surgery; however, these differences were not statistically significant. At 60 and 90 min after the start of surgery, the high-concentration group showed statistically lower MAP and SBP than the low-concentration group (mean arterial pressure, base; $p = 0.692$, intubation; $p = 0.765$, 30 min; $p = 0.121$, 60 min; $p = 0.006$, 90 min; $p = 0.025$, systolic

Table 1 Surgical grading scoring system designed specifically for use in endoscopic sinus surgery

Grade	Assessment
0	No bleeding (cadaveric conditions)
1	Slight bleeding – no suction required
2	Slight bleeding – occasional suction required
3	Slight bleeding – frequent suctioning required; bleeding threatens surgical field a few seconds after suction is removed
4	Moderate bleeding – frequent suctioning required and bleeding threatens surgical field directly after suction is removed
5	Severe bleeding – constant suctioning required; bleeding appears faster than can be removed by suction; surgical field severely threatened and surgery usually not possible




Fig. 1 Subject flow diagram

Table 2 Demographic data and clinical characteristics of patients

	Group LR (n = 27)	Group HR (n = 27)
Age (yr)	44 ± 12.0	47.1 ± 13.0
Gender (M/F)	9/18	9/18
Height (cm)	167.1 ± 8.8	167.6 ± 9.0
Weight (kg)	69.7 ± 13.0	69.1 ± 14.3
Body mass index (kg/m ²)	25.0 ± 4.1	24.5 ± 3.4
ASA (I/II)	10/17	11/16
Operation time (min)	108.3 ± 30.0	102.8 ± 22.8
Anesthesia time (min)	138.3 ± 28.2	135.7 ± 22.0

Values are number or mean ± SD

Group LR Low remifentanyl group, Group HR High remifentanyl group, ASA American Society of Anesthesiologists physical status

Table 3 Haemodynamic parameters

	Group LR (n = 27)	Group HR (n = 27)
Cardiac output, Base	7.20 ± 1.45	6.31 ± 2.34
Cardiac output, Intubation	7.34 ± 1.32	5.87 ± 1.81*
Cardiac output, 30	6.32 ± 1.28	5.00 ± 1.53*
Cardiac output, 60	6.45 ± 1.47	4.98 ± 1.56*
Cardiac output, 90	6.83 ± 1.37	5.18 ± 1.83*
Stroke volume, Base	92.4 ± 14.4	87.8 ± 20.7
Stroke volume, Intubation	88.2 ± 14.5	83.9 ± 17.0
Stroke volume, 30	89.3 ± 16.1	82.5 ± 16.9
Stroke volume, 60	88.5 ± 16.4	81.4 ± 18.1
Stroke volume, 90	88.1 ± 14.9	84.8 ± 19.8

The values are measured by non-invasive cardiac monitoring with CSN-1901. Base: preoperative control values; Intubation: immediately after intubation; 30, 60, and 90: 30 min, 60 min, and 90 min, respectively, after beginning the operation

* $p < 0.05$ compared to Group LR

arterial pressure, base; $p = 0.786$, intubation; $p = 0.144$, 30 min; $p = 0.081$, 60 min; $p = 0.039$, 90 min; $p = 0.019$).

Surgical conditions (Table 4) did not show significant differences between the two groups at 30 and 60 min after the start of surgery. However, at 90 min after the start of surgery, the high-concentration group

showed a significantly lower score than the low-concentration group (surgical score, 30 min; $p = 0.315$, 60 min; $p = 0.269$, 90 min; $p = 0.021$). There was no significant difference between the two groups in terms of

postoperative pain, nausea, and vomiting (VAS score, $p=0.991$, PONV score, $p=0.077$).

Discussion

The most important findings of this study are a significant decrease in the surgical score and cardiac output in the high-concentration remifentanyl group compared to the low-concentration group. Non-invasive cardiac monitoring was used to confirm that this decrease is due to a reduction in cardiac output primarily attributed to the decrease in heart rate induced by remifentanyl, rather than a decrease in stroke volume.

These findings have clinical significance as successful endoscopic sinus surgery relies on accurately identifying anatomical structures. Improved surgical conditions and enhanced visibility contribute to more precise surgical maneuvers and potentially reduce the risk of complications associated with increased bleeding, such as postoperative hemorrhage, cerebrospinal fluid leakage, and visual loss [7]. To mitigate these risks, the use of the reverse Trendelenburg position, topical decongestants, and vasoconstrictors has been suggested [8]. Additionally, controlled hypotension using general anesthesia has been employed to reduce bleeding during endoscopic sinus surgery [9]. The use of drugs such as vasodilators, sodium nitroprusside, or beta-blockers has also been proposed to lower blood pressure [10–12].

Total intravenous anesthesia using the intravenous anesthetic, propofol and the opioid, remifentanyl is widely used to minimize intraoperative bleeding by reducing cardiac output without rapidly decreasing systemic vascular resistance [3]. This effect is likely due to the bradycardia-inducing effect of remifentanyl, along with its blood pressure-lowering effect [13]. In this study, we confirmed a significant decrease in heart rate in the high-concentration group compared to the low-concentration group using a non-invasive cardiac monitoring device. Several reports suggest that the bradycardic effect of remifentanyl is associated with its central vagotonic effect [14].

Although a significant decrease in cardiac output was observed in the high-concentration group, stroke volume did not show a significant difference between the two groups. Based on these results, the decrease in cardiac output in the high-concentration group appears to be more strongly related to the decrease in heart rate than to the decrease in stroke volume. Cheong et al. [15] reported no proportional decrease in myocardial contractility with

increased remifentanyl usage, nor a compensatory increase in myocardial contractility with a decrease in heart rate. Manola et al. [16] found that the blood pressure-lowering effect of remifentanyl was due to the reduction of cardiac output rather than peripheral vasodilation.

In this study, cardiac output and stroke volume were measured using non-invasive cardiac monitoring (CSN-1901). The CSN-1901 monitoring system is based on pulse wave transit time and indirectly measures cardiac output and stroke volume through the R-wave of the electrocardiogram, the pulse waves of the pulse oximeter, and blood pressure. Traditionally, cardiac output has been measured invasively, such as with a pulmonary artery catheter, but the use of non-invasive methods is increasing while invasive methods are declining [17, 18]. Saugel et al. [17] compared the types and mechanisms of non-invasive cardiac monitoring with invasive measurement methods, and Jeon et al. [19] reported that using the CSN-1901 is helpful for estimating intravascular volume status.

It is important to acknowledge limitations of this study. Firstly, the evaluation of surgical conditions using the Boezaart grading scale, while widely used, is subjective and lacks standardization. Athanasiadis et al. [2] reported that most reported scores on the Boezaart grading scale were 2 or 3 points, making it difficult to detect subtle differences in the surgical field. Additionally, inter-rater reliability may vary, and reviewer bias is possible. Secondly, the study only measured cardiac output and stroke volume through non-invasive cardiac monitoring based on pulse wave transit time, which may not provide a comprehensive assessment compared to invasive methods like pulmonary artery catheterization or transesophageal echocardiography. Further studies comparing different methods of measuring cardiac output could provide more insights. Also, this study had a relatively small sample size, potentially limiting the ability to generalize the results to a broader population. Furthermore, the inclusion criteria restricted participation to patients classified as ASA I or II, excluding those with more severe health conditions, which could introduce bias. Additionally, the study was conducted in a single hospital, which may hinder the generalizability of the findings to hospitals in other regions or countries with different healthcare systems and care standards. Furthermore, long term surgical outcomes, length of hospital stay, and patient satisfaction may be targeted for future research.

In conclusion, the findings of this study support the use of high-concentration remifentanyl during endoscopic

(See figure on next page.)

Fig. 2 **a** Changes of heart rate in groups LR and HR. Base: preoperative control values; Intubation: right after intubation; HR 30, 60, and 90: 30, 60, and 90 respective min after beginning the operation. * $p < 0.05$ compared to Group LR. **b** Changes of mean arterial pressure in groups LR and HR. Base: preoperative control values; Intubation: right after intubation; HR 30, 60, and 90: 30, 60, and 90 respective min after beginning the operation. * $p < 0.05$ compared to Group LR. **c** Changes of systolic arterial pressure in groups LR and HR. Base: preoperative control values; Intubation: right after intubation; HR 30, 60, and 90: 30, 60, and 90 respective min after beginning the operation. * $p < 0.05$ compared to Group LR




Fig. 2 (See legend on previous page.)

Table 4 Changes of surgical scores and other parameters during endoscopic sinus surgery

	Group LR (n = 27)	Group HR (n = 27)
Surgical score, 30	2.33 ± 0.62	2.56 ± 0.63
Surgical score, 60	2.67 ± 0.62	2.44 ± 0.51
Surgical score, 90	2.80 ± 0.68	2.25 ± 0.58*
Total propofol dose (mg)	1127.4 ± 374.5	984.2 ± 304.1
Total remifentanyl dose (mcg)	1221.2 ± 347.3	2192 ± 719.2*
VAS	4.19 ± 2.24	4.19 ± 2.35
PONV	0.11 ± 0.32	0.00 ± 0.00

VAS Visual analogue score, PONV Postoperative nausea and vomiting

* $p < 0.05$ compared to Group LR

sinus surgery to improve surgical conditions and reduce bleeding. The decrease in the surgical score and cardiac output in the high-concentration group indicates enhanced visibility and potential benefits for successful surgical outcomes. However, the subjective nature of the surgical grading scale and the limitations of non-invasive cardiac monitoring should be considered when interpreting the results. Additionally, a recent meta-analysis indicated that TIVA appears to have advantages in terms of visibility scores and blood loss during endoscopic sinus surgery compared to inhalational anesthesia. However, the inconsistency observed when stratifying the results based on the use of remifentanyl and various inhaled anesthetics emphasizes the need for further investigation [20]. Further research exploring standardized evaluation methods and comparing different techniques for measuring cardiac output is warranted to strengthen the evidence base for optimizing anesthesia protocols in endoscopic sinus surgery.

Acknowledgements

The authors thank the Hanyang University E-world center for considerable help during the preparation of the manuscript.

Authors' contributions

JHJ, CWP, YJY, DJL, SYC: revised this manuscript. All authors have read and approved final manuscript.

Funding

Not applicable.

Availability of data and materials

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Declarations**Ethics approval and consent to participate**

This study was approved by the the hospital's institutional review board (Hanyang University Guri Hospital Institutional Review Board, GURI 2021-03-041-006) and registered with the clinical research information service centre (KCT0006453, Date of registration: 17/08/2021, Principal Investigator: SY Cho). This study was in accordance with the declaration of Helsinki and performed in accordance with the relevant guidelines and regulations. All patients voluntarily participated in the study and signed informed consent before the surgery.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 18 April 2023 Accepted: 22 August 2023

Published online: 29 August 2023

References

1. Cho K, Lee JY, Park SK, Cheong SH, Lee KM, Lim SH, et al. Comparison of surgical conditions during propofol or desflurane anesthesia for endoscopic sinus surgery. *Korean J Anesthesiol*. 2012;63:302–7.
2. Athanasiadis T, Beule A, Embate J, Steinmeier E, Field J, Wormald PJ. Standardized video-endoscopy and surgical field grading scale for endoscopic sinus surgery: a multi-centre study. *Laryngoscope*. 2008;118:314–9.
3. Brunner JP, Levy JM, Ada ML, Tipirneni KE, Barham HP, Oakley GM, et al. Total intravenous anesthesia improves intraoperative visualization during surgery for high-grade chronic rhinosinusitis: a double-blind randomized controlled trial. *Int Forum Allergy Rhinol*. 2018;8:1114–22.
4. Kim SH, Oh CS, Yoon TG, Cho MJ, Yang JH, Yi HR. Total intravenous anaesthesia with high-dose remifentanyl does not aggravate post-operative nausea and vomiting and pain, compared with low-dose remifentanyl: a double-blind and randomized trial. *ScientificWorldJournal*. 2014;2019(2014):724753.
5. Kim D, Lim HS, Kim MJ, Jeong W, Ko S. High-dose intraoperative remifentanyl infusion increases early postoperative analgesic consumption: a prospective, randomized, double-blind controlled study. *J Anesth*. 2018;32(6):886–92.
6. Boezaart AP, van der Merwe J, Coetzee A. Comparison of sodium nitroprusside and esmolol-induced controlled hypotension for functional endoscopic sinus surgery. *Can J Anaesth*. 1995;42:373–6.
7. Stankiewicz JA, Lal D, Connor M, Welch K. Complications in endoscopic sinus surgery for chronic rhinosinusitis: a 25-year experience. *Laryngoscope*. 2011;121:2684–701.
8. DeConde AS, Thompson CF, Wu EC, Suh JD. Systematic review and meta-analysis of total intravenous anesthesia and endoscopic sinus surgery. *Int Forum Allergy Rhinol*. 2013;3:848–54.
9. Ahn H, Chung S-K, Dhong H-J, Kim H, Ahn J, Lee S, et al. Comparison of surgical conditions during propofol or sevoflurane anaesthesia for endoscopic sinus surgery. *Br J Anaesth*. 2008;100:50–4.
10. Kelly EA, Gollapudi S, Riess ML, Woelck HJ, Loehrl TA, Poetker DM. Quality of surgical field during endoscopic sinus surgery: a systematic literature review of the effect of total intravenous compared to inhalational anesthesia. *Int Forum Allergy Rhinol*. 2013;3:474–81.
11. Cho SY, Cheong M, Kim KH, Kim DW, Jun JH, Suh JK, et al. The comparison of propofol and sodium nitroprusside in induced hypotension undergoing endoscopic sinus surgery. *Korean J Anesthesiol*. 1998;34:359–64.
12. Nekhendzy V, Lemmens HJM, Vaughan WC, Hepworth EJ, Chiu AG, Church CA, et al. The effect of deliberate hypercapnia and hypocapnia on intraoperative blood loss and quality of surgical field during endoscopic sinus surgery. *Anesth Analg*. 2007;105:1404–9.
13. Degoute C-S, Ray M-J, Manchon M, Dubreuil C, Bannillon V. Remifentanyl and controlled hypotension; comparison with nitroprusside or esmolol during tympanoplasty. *Can J Anaesth*. 2001;48:20–7.
14. Shinohara K, Aono H, Unruh GK, Kindscher JD, Goto H. Suppressive effects of remifentanyl on hemodynamics in baro-denervated rabbits. *Can J Anaesth*. 2000;47:361–6.
15. Cheong S-H, Park T-S, Lee S-E, Kim Y-H, Lim S-H, Lee J-H, et al. Measurement of hemodynamic variables using impedance cardiography on remifentanyl-propofol infusion during anesthetic induction. *Korean J Anesthesiol*. 2007;53:42–7.
16. Manola M, De Luca E, Moscillo L, Mastella A. Using remifentanyl and sufentanil in functional endoscopic sinus surgery to improve surgical conditions. *ORL J Otorhinolaryngol Relat Spec*. 2005;67:83–6.

17. Saugel B, Thiele RH, Hapfelmeier A, Cannesson M. Technological assessment and objective evaluation of minimally invasive and noninvasive cardiac output monitoring systems. *Anesthesiology*. 2020;133:921–8.
18. Nguyen LS, Squara P. Non-invasive monitoring of cardiac output in critical care medicine. *Front Med*. 2017;4:200.
19. Jeon WJ, Shin WJ, Yoon YJ, Park CW, Shim JH, Cho SY. Anesthetics management of a renal angiomyolipoma using pulse pressure variation and non-invasive cardiac output monitoring: a case report. *World J Clin Cases*. 2022;10:8656–61.
20. Moffatt DC, McQuitty RA, Wright AE, Kamucheka TS, Haider AL, Chaaban MR. Evaluating the role of anesthesia on intraoperative blood loss and visibility during endoscopic sinus surgery: a meta-analysis. *Am J Rhinol Allergy*. 2021;35(5):674–84.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

